Anaroxyl - 2.5 MG

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Monosemicarbazone Adrenochrome

Manufacturer : Nuvista Pharma Ltd

Best Price * TK 197.60

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - Anaroxyl - 2.5 MG

Description

Generic Name

Adrenochrome Monosemicarbazone

Precaution

Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.

Indication

Capillary bleeding, Haemoptysis, Haematuria, Retinal hemorrhage,Se condary hemorrhage, Menorrhagia.

Contra Indication

Should not be administered to patients with hypersensitivity.

Dose

N/A

Side Effect

Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Carbazochrome is an oxidation product of adrenaline (epinephrine). It has been used as a haemostatic agent.

Interaction

No specific drug interaction has been demonstrated.

Pregnancy Category Note

N/A

Adult Dose

Oral As a haemostatic Adult: 10-30 mg tid. Injection As a haemostatic Adult: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion. Pre-operative: 2-6ml at suitable intervals. Post-operative: 1-2ml every 2hrs. Non-surgical: 2-4ml tid.

Child Dose

Child <6yrs: 1-2ml tid.

Renal Dose

N/A

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.